JP2006519223A - 2,2,3,3−テトラメチルシクロプロパンカルボン酸の新規アミド誘導体 - Google Patents

2,2,3,3−テトラメチルシクロプロパンカルボン酸の新規アミド誘導体 Download PDF

Info

Publication number
JP2006519223A
JP2006519223A JP2006502646A JP2006502646A JP2006519223A JP 2006519223 A JP2006519223 A JP 2006519223A JP 2006502646 A JP2006502646 A JP 2006502646A JP 2006502646 A JP2006502646 A JP 2006502646A JP 2006519223 A JP2006519223 A JP 2006519223A
Authority
JP
Japan
Prior art keywords
group
alkyl
sulfonamide
derivative compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006502646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006519223A5 (cg-RX-API-DMAC10.html
Inventor
メイア ビアラー、
ボリス ヤゲン、
エヤル ソボル、
ダン カウフマン、
Original Assignee
イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL15469403A external-priority patent/IL154694A0/xx
Application filed by イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム filed Critical イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム
Publication of JP2006519223A publication Critical patent/JP2006519223A/ja
Publication of JP2006519223A5 publication Critical patent/JP2006519223A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/08—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/52—Y being a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
JP2006502646A 2003-02-28 2004-02-26 2,2,3,3−テトラメチルシクロプロパンカルボン酸の新規アミド誘導体 Pending JP2006519223A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL15469403A IL154694A0 (en) 2003-02-28 2003-02-28 New amide derivatives of 2,2,3,3,-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them
IL15775103A IL157751A0 (en) 2003-02-28 2003-09-04 New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them
PCT/IL2004/000193 WO2004076432A1 (en) 2003-02-28 2004-02-26 New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid

Publications (2)

Publication Number Publication Date
JP2006519223A true JP2006519223A (ja) 2006-08-24
JP2006519223A5 JP2006519223A5 (cg-RX-API-DMAC10.html) 2007-04-12

Family

ID=32715250

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006502646A Pending JP2006519223A (ja) 2003-02-28 2004-02-26 2,2,3,3−テトラメチルシクロプロパンカルボン酸の新規アミド誘導体

Country Status (7)

Country Link
US (1) US7232929B2 (cg-RX-API-DMAC10.html)
EP (1) EP1603891B1 (cg-RX-API-DMAC10.html)
JP (1) JP2006519223A (cg-RX-API-DMAC10.html)
AT (1) ATE396980T1 (cg-RX-API-DMAC10.html)
DE (1) DE602004014115D1 (cg-RX-API-DMAC10.html)
IL (1) IL157751A0 (cg-RX-API-DMAC10.html)
WO (1) WO2004076432A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004098A1 (en) * 2003-07-28 2006-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds useful for treating neurological disorders
DE102004010194A1 (de) * 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
DE102004010207A1 (de) * 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
JP2010519287A (ja) 2007-02-21 2010-06-03 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド α−ハロシクロプロピルカルボキシ化合物およびα−アルキルシクロプロピルカルボキシ化合物ならびにそれらの使用
CA2842455A1 (en) * 2011-08-05 2013-02-14 Sucampo Ag Method for treating schizophrenia

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA74202B (en) 1973-01-11 1974-11-27 Hexachimie New amine derivatives of 2,2-diaryl cyclopropanes
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
SE9303274D0 (sv) 1993-10-07 1993-10-07 Astra Ab Novel phenylethyl and phenylproplamines
IL108595A (en) 1994-02-08 1998-09-24 Yissum Res Dev Co History of Carboxylic Acid 2,2,3,3 Tetramethyl Cyclophen (ACMT) (Process for their Preparation and Pharmaceutical Preparations Containing Them)
IL120006A (en) 1997-01-14 2000-12-06 Yissum Res Dev Co Valnoctamide stereoisomers and a method for their synthesis and separation
WO1999048859A1 (en) 1998-03-20 1999-09-30 Bristol-Myers Squibb Company Aryloxyanilides and related compounds
IL124118A (en) 1998-04-16 2007-09-20 Yissum Res Dev Co Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, method for their synthesis and pharmaceutical compositions containing them
US6969732B2 (en) 1999-04-12 2005-11-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, a method for their synthesis and pharmaceutical compositions containing them
US6555585B2 (en) 2000-07-21 2003-04-29 Teva Pharmaceutical Industries, Ltd. Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
US6323365B1 (en) 2000-07-28 2001-11-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Active derivative of valproic acid for the treatment of neurological and psychotic disorders and a method for their preparation
DK1311256T3 (da) 2000-08-17 2005-11-28 Teva Pharma Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
US6610326B2 (en) 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
WO2003000654A1 (en) 2001-06-26 2003-01-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Valproyltaurinamide derivatives as anticonvulsant and cns active agents
IL147953A (en) 2002-02-01 2008-04-13 Meir Bialer Derivatives and pharmaceutical compositions of n-hydroxymethyl tetramethylcyclopropyl-
IL156203A0 (en) 2003-05-29 2003-12-23 Yissum Res Dev Co Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
WO2005009430A1 (en) 2003-07-28 2005-02-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds useful for treating neurological disorders

Also Published As

Publication number Publication date
US20060148861A1 (en) 2006-07-06
US7232929B2 (en) 2007-06-19
EP1603891B1 (en) 2008-05-28
DE602004014115D1 (de) 2008-07-10
IL157751A0 (en) 2004-03-28
ATE396980T1 (de) 2008-06-15
WO2004076432A1 (en) 2004-09-10
EP1603891A1 (en) 2005-12-14

Similar Documents

Publication Publication Date Title
KR102313757B1 (ko) 펩타이드 수용체 조절제로서의 n-우레아 치환된 아미노산의 유도체
JP2015502924A (ja) N−ホルミルペプチド受容体様1(fprl−1)受容体モジュレーターとしてのアリール尿素誘導体
HUP0103884A2 (hu) Arilszulfonanilidkarbamid-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
US5045565A (en) Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain
EA011167B1 (ru) Производные сульфонамида для лечения заболеваний
OA12631A (fr) Amides d'acide anthranilique avec une chaîne latérale hétéroarylsulfonyle, procédé our leur préparation, leur utilisation comme médeicament ou comme agent de diagnostic et préparations pharmaceutiquescontenant lesdits composés.
EP2646030A1 (en) Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
US20190322698A1 (en) Water-soluble allopregnenolone derivative and use thereof
JPH0576939B2 (cg-RX-API-DMAC10.html)
AU2015264021A1 (en) Imidazole derivatives as formyl peptide receptor modulators
PL194745B1 (pl) Podstawiony 2-benzyloamino-2-fenylo-acetamid, zawierająca go kompozycja farmaceutyczna i zastosowanie
NZ223790A (en) Beta-aminoethyl-substituted phenyl derivatives and pharmaceutical compositions thereof
RU2703725C1 (ru) Производные фенилкарбамата в качестве модуляторов формилпептидного рецептора
CH678621A5 (cg-RX-API-DMAC10.html)
WO2002030881A1 (de) Sulfonylguanidine
CN103384522B (zh) 咖啡酸衍生物和它们在改善神经细胞生存力中的用途
US7232929B2 (en) Amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid
EP1594485A2 (en) Compositions containing substituted quinolines and substituted diphenyl sulfones and methods of use
WO2018153212A1 (zh) 秋水仙碱衍生物、其制备方法及医药用途
US20160340318A1 (en) 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators
US20150291511A1 (en) Carbamoyl hydrazine derivatives as formyl peptide modulators
WO2003064374A1 (en) Derivatives and pharmaceutical compositions of n-hydroxyalkyl tetramethylcyclopropane-carboxamide, having anti-epileptic, neurological, and cns activity, and method for their preparation
JP2025510388A (ja) ベンズアミドエナミノン誘導体及びその使用方法
CN115969991A (zh) 一种麻醉药的结合物及其制备方法和应用
CN119731174A (zh) 取代的咪唑并[1,2-a]吡啶化合物及其在治疗和预防纤维化中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100713